Kiora Pharmaceuticals Stock Three Year Return

KPRX Stock

USD 3.57 0.12 3.48%

Kiora Pharmaceuticals fundamentals help investors to digest information that contributes to Kiora Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kiora Stock. The fundamental analysis module provides a way to measure Kiora Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiora Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kiora Pharmaceuticals Company Three Year Return Analysis

Kiora Pharmaceuticals' Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.

Three Year Return

(Mean of Monthly Returns - 1)

X

100%

More About Three Year Return | All Equity Analysis

Kiora Three Year Return Driver Correlations

Understanding the fundamental principles of building solid financial models for Kiora Pharmaceuticals is extremely important. It helps to project a fair market value of Kiora Stock properly, considering its historical fundamentals such as Three Year Return. Since Kiora Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kiora Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kiora Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Property Plant Equipment	Capital Stock	Long Term Debt	Short Long Term Debt
Total Assets		0.93	-0.68	-0.82	0.31	0.43	-0.87	0.76	-0.48	0.49	0.47	-0.73	0.61	0.74	0.67	0.79	0.77	0.52	-0.66	-0.17	-0.17
Total Stockholder Equity	0.93		-0.69	-0.79	0.3	0.47	-0.99	0.76	-0.55	0.51	0.42	-0.69	0.43	0.7	0.53	0.73	0.71	0.43	-0.63	-0.26	-0.26
Net Debt	-0.68	-0.69		0.31	-0.15	-0.14	0.69	-0.95	0.67	-0.61	-0.45	0.31	-0.03	-0.28	-0.06	-0.34	-0.38	-0.16	0.07	-0.11	-0.11
Retained Earnings	-0.82	-0.79	0.31		-0.11	-0.77	0.7	-0.48	0.32	-0.26	-0.34	0.91	-0.7	-0.92	-0.78	-0.83	-0.83	-0.82	0.84	0.64	0.64
Accounts Payable	0.31	0.3	-0.15	-0.11		0.01	-0.29	0.18	-0.02	-0.05	0.37	0.11	0.21	-0.13	0.05	-0.06	-0.15	0.0	-0.02	0.18	0.18
Net Receivables	0.43	0.47	-0.14	-0.77	0.01		-0.41	0.35	-0.22	-0.03	0.09	-0.67	0.61	0.69	0.61	0.47	0.47	0.88	-0.57	-0.81	-0.81
Total Liab	-0.87	-0.99	0.69	0.7	-0.29	-0.41		-0.74	0.55	-0.5	-0.35	0.63	-0.34	-0.64	-0.46	-0.67	-0.66	-0.32	0.58	0.19	0.19
Total Current Assets	0.76	0.76	-0.95	-0.48	0.18	0.35	-0.74		-0.53	0.61	0.48	-0.46	0.16	0.44	0.18	0.44	0.49	0.36	-0.19	-0.07	-0.07
Short Term Debt	-0.48	-0.55	0.67	0.32	-0.02	-0.22	0.55	-0.53		-0.3	-0.29	0.28	-0.13	-0.29	-0.18	-0.29	-0.29	-0.16	0.24	0.14	0.14
Common Stock	0.49	0.51	-0.61	-0.26	-0.05	-0.03	-0.5	0.61	-0.3		0.37	-0.3	-0.2	0.34	-0.05	0.37	0.41	-0.01	0.11	-0.04	-0.04
Current Deferred Revenue	0.47	0.42	-0.45	-0.34	0.37	0.09	-0.35	0.48	-0.29	0.37		-0.05	0.02	0.06	0.02	0.02	0.02	0.1	-0.03	-0.17	-0.17
Good Will	-0.73	-0.69	0.31	0.91	0.11	-0.67	0.63	-0.46	0.28	-0.3	-0.05		-0.59	-0.99	-0.71	-0.93	-0.96	-0.79	0.83	0.51	0.51
Intangible Assets	0.61	0.43	-0.03	-0.7	0.21	0.61	-0.34	0.16	-0.13	-0.2	0.02	-0.59		0.61	0.94	0.62	0.53	0.72	-0.74	-0.31	-0.31
Net Tangible Assets	0.74	0.7	-0.28	-0.92	-0.13	0.69	-0.64	0.44	-0.29	0.34	0.06	-0.99	0.61		0.74	0.94	0.96	0.78	-0.82	-0.56	-0.56
Deferred Long Term Liab	0.67	0.53	-0.06	-0.78	0.05	0.61	-0.46	0.18	-0.18	-0.05	0.02	-0.71	0.94	0.74		0.71	0.67	0.71	-0.81	-0.35	-0.35
Net Invested Capital	0.79	0.73	-0.34	-0.83	-0.06	0.47	-0.67	0.44	-0.29	0.37	0.02	-0.93	0.62	0.94	0.71		0.97	0.59	-0.83	-0.3	-0.3
Net Working Capital	0.77	0.71	-0.38	-0.83	-0.15	0.47	-0.66	0.49	-0.29	0.41	0.02	-0.96	0.53	0.96	0.67	0.97		0.63	-0.79	-0.32	-0.32
Property Plant Equipment	0.52	0.43	-0.16	-0.82	0.0	0.88	-0.32	0.36	-0.16	-0.01	0.1	-0.79	0.72	0.78	0.71	0.59	0.63		-0.62	-0.69	-0.69
Capital Stock	-0.66	-0.63	0.07	0.84	-0.02	-0.57	0.58	-0.19	0.24	0.11	-0.03	0.83	-0.74	-0.82	-0.81	-0.83	-0.79	-0.62		0.4	0.4
Long Term Debt	-0.17	-0.26	-0.11	0.64	0.18	-0.81	0.19	-0.07	0.14	-0.04	-0.17	0.51	-0.31	-0.56	-0.35	-0.3	-0.32	-0.69	0.4		1.0
Short Long Term Debt	-0.17	-0.26	-0.11	0.64	0.18	-0.81	0.19	-0.07	0.14	-0.04	-0.17	0.51	-0.31	-0.56	-0.35	-0.3	-0.32	-0.69	0.4	1.0

Click cells to compare fundamentals

Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.

Competition

Predict Kiora Pharmaceuticals

Kiora Return On Tangible Assets

Return On Tangible Assets

(2.68)

At this time, Kiora Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year.

Based on the latest financial disclosure, Kiora Pharmaceuticals has a Three Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Kiora Three Year Return Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiora Pharmaceuticals' direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics of similar companies.

Kiora Pharmaceuticals is currently under evaluation in three year return category among its peers.

Kiora Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kiora Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kiora Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Kiora Fundamentals

	Return On Equity	0.14
	Return On Asset	0.13
	Profit Margin	0.20 %
	Operating Margin	(121.23) %
	Current Valuation	(18.25 M)
	Shares Outstanding	2.97 M
	Shares Owned By Insiders	2.30 %
	Shares Owned By Institutions	48.34 %
	Number Of Shares Shorted	39.65 K
	Price To Book	0.36 X
	Price To Sales	0.67 X
	Gross Profit	(5.14 M)
	EBITDA	(12.35 M)
	Net Income	(12.51 M)
	Cash And Equivalents	2.43 M
	Cash Per Share	2.64 X
	Total Debt	106.89 K
	Debt To Equity	0.02 %
	Current Ratio	1.53 X
	Book Value Per Share	7.14 X
	Cash Flow From Operations	(9.56 M)
	Short Ratio	0.27 X
	Earnings Per Share	16.53 X
	Target Price	30.33
	Number Of Employees	12
	Beta	-0.29
	Market Capitalization	10.75 M
	Total Asset	13.71 M
	Retained Earnings	(146.98 M)
	Working Capital	3.1 M
	Net Asset	13.71 M

About Kiora Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kiora Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC